IO Biotech (NASDAQ:IOBT - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.
IO Biotech Stock Performance
Shares of IO Biotech stock traded down $0.08 on Friday, reaching $1.81. 358,055 shares of the company were exchanged, compared to its average volume of 597,670. IO Biotech has a 1-year low of $0.66 and a 1-year high of $2.48. The firm has a market cap of $124.51 million, a price-to-earnings ratio of -1.21 and a beta of 0.44. The company's 50-day moving average is $1.67 and its two-hundred day moving average is $1.22.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in IO Biotech stock. Jane Street Group LLC acquired a new stake in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,717 shares of the company's stock, valued at approximately $26,000. 54.76% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on IOBT. HC Wainwright reiterated a "buy" rating on shares of IO Biotech in a report on Wednesday, May 14th. Wall Street Zen raised IO Biotech to a "sell" rating in a report on Saturday, June 14th.
View Our Latest Research Report on IOBT
IO Biotech Company Profile
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Recommended Stories

Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.